Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi: PA GOODDOCTOR (01833.HK) Rated at Buy w/ TP $18 as 2025 NP Beats
Recommend 4 Positive 4 Negative 6 |
||||
|
||||
|
PA GOODDOCTOR (01833.HK)'s 2025 revenue was RMB5.468 billion, up 14% YoY, while net profit amounted to RMB380 million, marking a significant YoY growth of 366%, Citi Research issued a research report saying. Its full-year revenue was in line with expectation, while net profit beat the estimations of the market/ broker by 37%/ 32%. During the period, its gross margin increased from 31.7% in 2024 to 32.4%, and the net profit margin rose from 1.7% to 6.9%. With AI empowerment and improved efficiency management, its adjusted net profit margin hiked from 3.3% to 7.6%. Therefore, Citi Research currently rated PA GOODDOCTOR at Buy, with a target price of $18. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
